A carregar...
Pharmacokinetics, Immunogenicity, and Safety of Weekly Dosing of Brentuximab in Pediatric Patients with Hodgkin Lymphoma
PURPOSE: Because of the observed success of phase I/II trials, the novel anti-CD30 agent brentuximab vedotin is now being evaluated as a frontline agent in the high-risk pediatric Hodgkin lymphoma trial HLHR13. The objectives of this study were to evaluate the pharmacokinetic variability during week...
Na minha lista:
| Publicado no: | Cancer Chemother Pharmacol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5206991/ https://ncbi.nlm.nih.gov/pubmed/27837256 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3180-x |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|